Screening of the central nervous system in children with invasive pulmonary aspergillosis by Broenen, Emmi et al.
Screening of the central nervous system in children with invasive
pulmonary aspergillosis
Emmi Broenen a, Annelies Mavinkurve-Groothuis a, Karin Kamphuis-van Ulzen b,
Roger Brüggemann c,e, Paul Verweij d,e, Adilia Warris a,e,n
a Department of Pediatrics, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
b Department of Radiology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
c Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
d Department of Medical Microbiology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
e Nijmegen Institute for Infection, Immunity and Inﬂammation, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen,
The Netherlands
a r t i c l e i n f o
Article history:
Received 10 January 2014
Received in revised form
31 January 2014
Accepted 3 February 2014
Keywords:
Aspergillosis
Central nervous system
Therapeutic drug monitoring
Screening
Pediatrics
Voriconazole
a b s t r a c t
The existing guidelines regarding the management of invasive pulmonary aspergillosis do not
recommend screening of the extra-pulmonary sites. Due to the fact that the presence of central nervous
system (CNS) aspergillosis will inﬂuence treatment decisions regarding which antifungal to use and the
aimed target concentrations of azoles in plasma, to be informed about dissemination of the infection to
the CNS is absolutely necessary. We demonstrate the need for a structured approach to screening of
pediatric patients for CNS aspergillosis.
& 2014 The Authors. International Society for Human and Animal Mycology. Published by Elsevier B.V.
1. Introduction
Children with hematological malignancies are at high risk for
developing invasive pulmonary aspergillosis (IPA) with a high
mortality rate [1–3], despite their currently good prognosis of
the underlying malignancy. The most frequent extra-pulmonary
site in children is the central nervous system (CNS) [4]. Central
nervous system involvement is reported in a frequency of 9–39%
with exceeding mortality rates of 88% and higher [3,4]. Voricona-
zole is the mainstay of systemic treatment for cerebral aspergillo-
sis due to its good penetration into the central nervous system.
This drug has substantially reduced the mortality rate to 65% [5].
To our knowledge, the existing guidelines regarding the man-
agement of persistent febrile neutropenia or invasive aspergillosis
[6–8] do not recommend screening of the extra-pulmonary sites in
the absence of localized signs and symptoms and/or in those
situations where a proven or probable IPA [9] has been diagnosed.
Due to the fact that the presence of CNS aspergillosis will inﬂuence
treatment decisions regarding which antifungal to use and the
aimed target concentrations of azoles in plasma, to be informed
about dissemination of the infection to the CNS is absolutely
necessary. We demonstrate the need for a structured approach
to screening of pediatric patients for CNS aspergillosis by using
two clinical cases to exemplify this. Next we discuss the possible
indications when to perform this diagnostic work-up.
2. Case
2.1. Case 1
An 8-year-old boy presented with an episode of febrile neu-
tropenia during his treatment for High Risk Acute Lymphoblastic
Leukemia (HR-ALL). Broad spectrum antibiotics were started and
galactomannan (GM) screening was performed according to our
local protocols (e.g., twice weekly during neutropenia irrespective
of fever). Galactomannan in serum showed an index of 0.6
(negativeo0.5) and suspicion of invasive aspergillosis was risen.
Treatment with voriconazole (8 mg/kg/day including loading dose
of 12 mg/kg/day) i.v. was started (day 0) and further diagnostic
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work-up was performed. Culture of the sputum was positive
for Aspergillus fumigatus. HRCT-thorax revealed ﬁve round densi-
ties and a cavity forming lesion resembling an air crescent sign,
suggestive of invasive pulmonary aspergillosis. Voriconazole
treatment was switched (day þ4) to oral formulation (200 mg
twice a day) due to a satisfactory clinical condition and he was
discharged on day 5. Two weeks after the boy was discharged from
the hospital he presented with fatigue, headache and vomiting
(day þ19). CT-cerebrum showed two large abscesses causing
midline shift (Fig. 1). CNS aspergillosis was suspected and surgical
drainage of one abscess was performed. Direct microscopy of the
ﬂuid revealed branching hyphae compatible with Aspergillus sp.,
although culture was negative. Ambisome (5 mg/kg/day) was
added to the voriconazole treatment (day þ22) since we could
either be facing an azole-resistant Aspergillus sp., or insufﬁcient
plasma concentrations resulting in suboptimal cerebral concentra-
tions of voriconazole. PCR analysis targeted at Cyp51A-mediated
resistance markers, as described previously [10], was performed
using the isolate recovered from sputum and directly on the
bronchoalveolar lavage (BAL) sample showing a wild type
Cyp51A-gene supporting azole susceptibility. In addition, a pre-
sumed adequate intralesional voriconazole concentration of
2.33 mg/L was found. Voriconazole was continued till 3 months
after end of chemotherapy (day þ477). He fully recovered from his
disseminated aspergillosis and is currently in a good clinical
condition.
2.2. Case 2
A 2.5-year-old girl, diagnosed with medium risk (MR) ALL,
presented with coughing, malaise and febrile neutropenia 1 month
after start of chemotherapy. During physical examination of the
lungs, bilateral bronchi were noticed. Blood and sputum cultures
were taken. Broad spectrum intravenous antibiotics were started
according to our local protocol. Four days after presentation,
serum GM showed an increased index (GMI) of 6.2. Voriconazole
(14 mg/kg/day) i.v. was started immediately (day 0). The next day a
HRCT-thorax was performed which showed ground glass aspect
areas in both lungs, peribronchial consolidations and a halo sign in
the right upper lobe suspect for an invasive fungal infection. A BAL
was performed and showed Aspergillus sp. by PCR and A. fumigatus
was cultured. GM index in BAL was 7.4. Susceptibility testing
showed an intermediate susceptibility of voriconazole (MIC
2.0 mg/L, determined according EUCAST guideline). Therefore,
trough plasma concentrations of voriconazole were targeted at
43 mg/L keeping in mind the increased chance of toxicity at
higher concentrations. Follow-up evaluation (day þ21) of the
pulmonary abnormalities after 3 weeks of antifungal treatment
showed only residual lesions. On day 28 of IV voriconazole
treatment the route of administration was switched to oral. Five
months later (day þ180), while under continued oral voriconazole
treatment with varying dosages (based on TDM) the patient was
admitted to our hospital with clinical signs of encephalopathy,
without focal neurological symptoms, in the presence of a toxic
voriconazole plasma concentration of 13.2 mg/L. Voriconazole was
immediately ceased for a temporary time period. MRI-cerebrum
showed multiple lesions with extensive amounts of edema,
especially in the right parietal lobe and the left frontal lobe
(Fig. 2). Trepanation of the occipital lesion was performed. The
biopsy showed fungal hyphae. Voriconazole level intralesional was
0.6 mg/L, with a plasma concentration of 0.51 mg/L at the time of
surgery. A. fumigatus (MIC 1 mg/L) was cultured from the cere-
brospinal ﬂuid and the GM index was increased (1.4) as well. Since
plasma concentrations decreased substantially (as demonstrated
in the rapid decline after cessation of voriconazole), antifungal
therapy was restarted (day þ185) and controlled by intensive
TDM. Four months after cessation of the antileukemic treatment,
voriconazole treatment was discontinued (day þ720). Cerebral
and pulmonary imaging show still residual lesions without clinical
symptoms.
3. Discussion
We describe two children both presenting with a CNS asper-
gillosis during treatment for IPA. In our opinion, the dissemination
of the IPA to the brain should not be considered as a treatment
failure in the presented cases, but infection of the brain most likely
has been present at the time IPA was diagnosed. Due to the fact
that neurological signs and symptoms were absent, imaging of the
brain was not performed initially. In retrospect, the fungal lesions
must have been developing during voriconazole treatment for IPA,
being an adequate treatment choice, although higher trough
concentrations in plasma would have been aimed for. In the latter
case we present, the elevated MIC of the Aspergillus isolate
requires even higher target concentrations and has been compli-
cating optimal treatment. In addition, surgical treatment could
have been considered in an earlier stage of disease [11]. This raises
the question if earlier screening of the central nervous system
Fig. 1. Patient 1: axial T2 (left) and T1 (right) contrast enhanced MRI-cerebrum showmultiple lesions intracerebral at the corticomedullary junction, with low T2 signal with
surrounding edema and rim enhancement.
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might have led to earlier detection of dissemination of the disease.
Consequently, improved and directed treatment options could
have been initiated and could have prevented the worsening
neurological condition as seen in the presented cases. The inci-
dence of dissemination of IPA to the CNS is not well known. Only
one study has analyzed the prevalence of CNS aspergillosis in the
presence of IPA in leukemic patients [12]. Of the 100 microbiolo-
gical proven invasive aspergillosis cases, 14 suffered from CNS
aspergillosis as well (incidence of 14%). Ten out of these 14
patients suffered from neurological symptoms being already on
antifungal treatment. A dismal outcome was observed, 11 of those
14 patients died (79%) and the diagnosis was conﬁrmed at autopsy.
Hagensee et al. showed that 87% of the Aspergillus brain abscesses
in post-BMT patients were secondary to invasive pulmonary
aspergillosis, neurological symptoms developed while on antifun-
gal therapy (amphotericin B) and most cases were diagnosed only
at autopsy [13]. Considering the dismal outcome of CNS aspergil-
losis, the late appearance of clinical symptoms, and the improved
therapeutic measurements for cerebral aspergillosis, a structured
screening program in case a diagnosis of probable or proven
aspergillosis is made, should be strongly considered.
The current guidelines do not make recommendations for
screening of the CNS in case of IPA [6–8]. In the clinical practice
guidelines for the management of aspergillosis of the Infectious
Diseases Society of America (IDSA) it is only mentioned that
aggressive diagnostic intervention is needed in patients with
documented invasive pulmonary aspergillosis and signs of neuro-
logical deﬁcits [7]. In the international pediatric fever and neu-
tropenia guideline, although not speciﬁc for the management of
invasive aspergillosis, it is mentioned that analysis of GM in CSF
might be considered in pediatric patients with a high-risk for
invasive fungal disease, and/or targeted imaging of extra-
pulmonary sites of clinically suspected areas of infection [6]. In
our opinion, imaging of the CNS should be performed upon
diagnosis of IPA irrespectively of neurological signs and symptoms,
due to the fact that they appear late in the course of disease.
Although limited evidence shows that GM in CSF can support a
diagnosis of probable CNS aspergillosis [14], it is questionable if it
is useful as a screening test for CNS aspergillosis.
MRI-cerebrum should be the screening instrument of choice to
detect intracranial fungal lesions [8]. The best timing for cerebral
screening remains a question. Radiologic images will depend on
the immune status. Based on our observations and those from
others, screening of the CNS by MRI should be preferably
performed after recovery of the neutrophils [15]. Voriconazole, if
possible along with surgical drainage, is ﬁrst choice therapy in CNS
aspergillosis [16], but needs to be combined with TDM [17].
Experts have suggested that if the localization of invasive asper-
gillosis, caused by voriconazole susceptible Aspergillus spp, is in
a less accessible area as the brain, higher trough concentrations in
plasma of greater than 2 mg/L should be aimed for [18,19]. Efforts
should be made to isolate the causative Aspergillus sp. from the
brain, especially when no isolate has been obtained from the
lungs. Azole resistance among A. fumigatus is an emerging pro-
blem and seems to have a predilection for brain tissue [20,21]
urging the need for a mycological diagnosis.
In summary, cerebral aspergillosis has a high mortality rate.
Presenting symptoms are often non-speciﬁc and become apparent
only late in the course of disease which may cause delay in
diagnosis associated with a worse outcome. In order to attempt
optimal treatment for patients with cerebral aspergillosis, screen-
ing patients with proven or probable IPA by MRI of the brain
is needed to detect concurrent cerebral aspergillosis before clinical
symptoms occurs. Early detection of cerebral aspergillosis will
lead to adequate and directed treatment regarding the choice of
an antifungal with sufﬁcient CNS penetration including the
optimal dose.
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